Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Kimberly Rath, PharmD, is a freelance health writer who previously worked as a clinical pharmacist with Elevance Health for a decade. She has also worked for Amerigroup and Sentara Group.

Articles

A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.

Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link

For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase inhibitors, many more trials are needed to pinpoint the best next steps 

Treating Double-Exposed Patients With CLL: A Continued Unmet Need

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Women living with HIV can reduce their risk of cervical cancer using a human papillomavirus (HPV) vaccine that is both cost-effective and effective in preventing the virus.

HPV Vaccination Cost-Effective at Preventing Cervical Cancer in Patients With HIV

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.

Semaglutide Eligibility Expands to Over Half of US Adults

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

ASCO 2024: Latest Data in Melanoma 

Video Series

ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma

Video content above is prompted by the following:

What is the value of long-term follow-up data in melanoma? How does this impact use of treatment regimens?

How do you foresee the role of combination therapies evolving in the treatment of melanoma over the next few years?

Videos

Evan J. Lipson, MD, from Johns Hopkins University School of Medicine contributes key updates in melanoma treatment presented at ASCO 2024 in Chicago, Illinois.

Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.

ASCO 2024: Addressing Unmet Needs in Melanoma Treatment and Management 

Dr Lipson continues his discussion as he highlights significant results from the NADINA trial.

Key Findings from the NADINA Trial at ASCO 2024

Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson.

ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management 

Dr Lipson provides insights surrounding combination therapies in melanoma management.

Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.

Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights

ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma

EP: 1.ASCO 2024: Addressing Unmet Needs in Melanoma Treatment and Management

EP: 2.Key Findings from the NADINA Trial at ASCO 2024

EP: 3.ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

EP: 4.ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma

EP: 5.Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

EP: 6.ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

EP: 7.Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights